Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer

International Journal of Cancer

Volumn 95, Issue 6, 2001, Pages 354-359

  Chang, Bao Li ^a   Zheng, Siqun L ^b   Isaacs, Sarah D ^c   Wiley, Kathy E ^c   Carpten, John D ^d   Hawkins, Gregory A ^b   Bleecker, Eugene R ^b   Walsh, Patrick C ^c   Trent, Jeffrey M ^d   Meyers, Deborah A ^b   Isaacs, William B ^c   Xu, Jianfeng ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Association; CYP17; Genetic; Hereditary; Linkage; Prostate cancer

Indexed keywords

ANDROGEN; CYTOCHROME P450 C17ALPHA; CYTOCHROME P450 ISOENZYME; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL CANCER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER;

ADULT; AGED; ALLELES; FAMILY HEALTH; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0035923250     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20011120)95:6<354::AID-IJC1062>3.0.CO;2-3     Document Type: Article

References (64)

1. Family history and the risk of prostate cancer
2. Mendelian inheritance of familial prostate cancer
3. Studies of genetic factors in prostate cancer in a twin population
4. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance
5. Hereditary and prostate cancer: A study of World War II veteran twins
6. Evidence for autosomal dominant inheritance of prostate cancer
7. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer
8. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
9. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics
10. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
11. Evidence for a prostate cancer susceptibility locus on the X chromosome
12. A genomic scan of families with prostate cancer identifies multiple regions of interest
13. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary
14. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
15. Molecular genetics and epidemiology of prostate carcinoma
16. Hormonal carcinogenesis
17. Prospective study of sex hormone levels and risk of prostate cancer
18. Cloning and sequence of the human gene for P450c17 (steroid 17 α-hydroxylase/17,20 lyase): Similarity with the gene for P450c21
19. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
20. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations
21. The relationship between the polymorphism in CYP17 gene with plasm hormone levels and breast cancer
22. A polymorphism in the CYP17 gene increase the risk fo breast cancer
23. Association between CYP17 gene polymorphism and risk of breast cancer in young women
24. A polymorphism in the CYP17 gene is associated with male breast cancer
25. No association between a polymorphism in the steroid metabolism gene CYP17 and the risk of breast cancer
26. Association between CYP17 polymorphisms and the development of breast cancer
27. Frequencies of the polymorphism in the regulatory region of the 17 α-hydroxylase-17,20lyase (CYP17) gene in hyperandrogenic states
28. CYP17 genotype and breast cancer risk
29. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
30. A polymorphism in the CYP17 gene is associated with prostate cancer risk
31. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population
32. Prostate cancer associated with CYP17 genotype
33. Increased risk of prostate cancer and benign prostate hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect
34. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
35. Comprehensive human genetic maps: Individual and sex-specific variation in recombination
36. Linkage map integration
37. Strategies for multilocus linkage analysis in humans
38. Faster sequential genetic linkage computations
39. Parametric and nonparametric linkage analysis: A unified multipoint approach
40. Allele-sharing models: LOD scores and accurate linkage tests
41. A class of tests for linkage using affected pedigree members
42. Distribution of the admixture test for the detection of linkage under heterogeneity
43. Implementing a unified approach to family based test of association
44. Genetic dissection of complex traits: Guideline for interpreting and reporting linkage results
45. The power to detect linkage in complex disease by means of simple LOD-score analyses
46. Further evidence for the increased power of LOD scores compared with nonparametric methods
47. A genome screen of multiplex sibships with prostate cancer
48. Genetic changes associated with prostate cancer in humans
49. Loss of the chromosomal region 10q23-25 in prostate cancer
50. Allelic loss on chromosome 10 in prostate adenocarcinoma
51. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer
52. Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer
53. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas
54. Molecular pathogenesis of malignant gliomas
55. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta
56. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
57. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
58. The future of genetic studies of complex human diseases
59. Effect of allelic heterogeneity on the power of the transmission disequilibrium test
60. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1
61. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men